Svante Paabo Wins 2022 Nobel Prize in Medicine

Secretary of the Nobel Committee for Physiology or Medicine Thomas Perlmann (R) announces the winner of the 2022 Nobel Prize in Physiology or Medicine Sweden's Svante Paabo, during a press conference at the Karolinska Institute in Stockholm, Sweden, on October 3, 2022. (AFP)
Secretary of the Nobel Committee for Physiology or Medicine Thomas Perlmann (R) announces the winner of the 2022 Nobel Prize in Physiology or Medicine Sweden's Svante Paabo, during a press conference at the Karolinska Institute in Stockholm, Sweden, on October 3, 2022. (AFP)
TT

Svante Paabo Wins 2022 Nobel Prize in Medicine

Secretary of the Nobel Committee for Physiology or Medicine Thomas Perlmann (R) announces the winner of the 2022 Nobel Prize in Physiology or Medicine Sweden's Svante Paabo, during a press conference at the Karolinska Institute in Stockholm, Sweden, on October 3, 2022. (AFP)
Secretary of the Nobel Committee for Physiology or Medicine Thomas Perlmann (R) announces the winner of the 2022 Nobel Prize in Physiology or Medicine Sweden's Svante Paabo, during a press conference at the Karolinska Institute in Stockholm, Sweden, on October 3, 2022. (AFP)

Scientist Svante Paabo won the 2022 Nobel Prize in Physiology or Medicine for his discoveries "concerning the genomes of extinct hominins and human evolution", the award-giving body said on Monday.

The prize, arguably among the most prestigious in the scientific world, is awarded by the Nobel Assembly of Sweden's Karolinska Institute and is worth 10 million Swedish crowns ($900,357).

It is the first of this year's batch of prizes.

Created in the will of Swedish dynamite inventor and wealthy businessman Alfred Nobel, the prizes for achievements in science, literature and peace have been awarded since 1901, though the economics prize is a later addition.

The COVID-19 pandemic has placed medical research center stage with many expecting that the development of the vaccines that have allowed the world to regain some sense of normality may eventually be rewarded.

Still, it typically takes many years for any given research to be honored, with the committees charged with picking the winners looking to determine its full value with some certainty amongst what is always a packed field of contenders.

This year's festivities should in any case mark the return of the Nobel banquet in Stockholm after a two-year hiatus due to the pandemic, an event redolent of old-world pomp and glamour after years of social distancing.

Last year's medicine prize went to Americans David Julius and Ardem Patapoutian for the discovery of receptors in the human skin that sense temperature and touch, converting the physical impact into nerve impulses.

Past winners in the field include a string of famous researchers, notably Alexander Fleming, who shared the 1945 prize for the discovery of penicillin, and Robert Koch, who won already in 1905 for his investigations of tuberculosis.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”